- The Best-Selling Drugs in the World By 2020 (fool.com)
..Humira's dominance as the best-selling drug in the world expected to come to an end in the coming years, look for these drugs to potentially take its spot…Last year global pharmaceutical sales topped the $1 trillion mark for the first time ever. By 2018…predicts sales will rise by another 30% to $1.3 trillion. This is a major growth opportunity for investors, but only if they understand what blockbuster drugs are on their ascent, and which ones could be on the decline…I'd keep my eye on a handful of therapies to step up as the best-selling drugs in the world by 2020.
- Harvoni (ledipasvir/sofosbuvir)
- Revlimid (lenalidomide)
- Aducanumab (investigational, BIIB037)
- Drugs just don’t get rejected much anymore, report says (fiercebiotech.com)
Picking apart biopharma’s protracted boom,…the vibe that getting drugs approved is simply much easier than it once was…. FDA has been green-lighting new drugs at an escalating rate for the past few years… some think the agency can go farther… 21st Century Cures Act,..contains a bevy of provisions designed to bring medicines to the market more quickly…The bill has faced staunch criticism from public health officials and media outlets, cautioning that there can be too much of a good thing, and improperly evaluated drugs can be just as dangerous to patients as no treatments at all.
- Stock slide makes biopharma deals more enticing for Gilead (and everyone else) (fiercepharma.com)
Analysts and investors may have been ready for Gilead Sciences to make an M&A (merger and acquisition) move before now. But with stocks on a slide, they might be glad Gilead hasn't yet… company is sitting on almost $15 billion in liquidity… biotech's stock losses mean deals are lots cheaper now than they were…the company is eyeing all sorts of deals…
- China’s much-hyped healthcare reform drive stuck in first gear (newsdaily.com)
Li Tiantian, a Chinese doctor turned tech entrepreneur, is a leading light of the country’s much-trumpeted healthcare reform drive. His medical networking platform DXY.com …has attracted funding from tech giants … reality is rather different… a lack of support by Beijing and obstacles working with China’s huge, fragmented public healthcare sector...
- Lilly, Sanofi, Novo among many pharma players to throw off big price gains in H1 (fiercepharma.com)
On the flip side, AstraZeneca, GSK and J&J stock prices contracted… The first half of the year has provided a good ride for Big Pharma and its investors with indices up in the U.S. and Europe. Even Japanese drugmakers avoided the side effects of China's stock market meltdown and saw values rise 23%. But, of course, averages come from the highs and the lows and some players have actually seen share price declines during this bull market.
- China to expand medical insurance for major illnesses (newsdaily.com)
China will expand medical insurance to cover all critical illnesses...State Council said 50 percent of the medical costs will be covered by insurance…healthcare … struggles with a scarcity of doctors, attacks by patients on medical staff and a fragmented drug distribution...